Neuroinflammation in Alzheimer's disease: Chemokines produced by astrocytes and chemokine receptors

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 12, 2014, Pages 8342-8355

  Liu, Chang ^a   Cui, Guohong ^b   Zhu, Meiping ^a   Kang, Xiangping ^a   Guo, Haidong ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Alzheimer's disease; Astrocytes; Chemokine receptors; Chemokines; Inflammation

Indexed keywords

CHEMOKINE; CHEMOKINE RECEPTOR;

ALZHEIMER DISEASE; ANIMAL; ASTROCYTE; HUMAN; IMMUNOLOGY; INFLAMMATION; METABOLISM; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; ASTROCYTES; CHEMOKINES; HUMANS; INFLAMMATION; RECEPTORS, CHEMOKINE;

EID: 84921521862     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Review

References (123)

1. Heneka MT, O'Banion MK, Terwel D and Kummer MP. Neuroinflammatory processes in Alzheimer's disease. J Neural Transm 2010; 117: 919-947.
2. Baik SH, Cha MY, Hyun YM, Cho H, Hamza B, Kim DK, Han SH, Choi H, Kim KH, Moon M, Lee J, Kim M, Irimia D and Mook-Jung I. Migration of neutrophils targeting amyloid plaques in Alzheimer's disease mouse model. Neurobiol Aging 2014; 35: 1286-1292.
3. Tuppo EE and Arias HR. The role of inflammation in Alzheimer's disease. Int J Biochem Cell Biol 2005; 37: 289-305.
4. Li C, Zhao R, Gao K, Wei Z, Yin MY, Lau LT, Chui D and Hoi Yu AC. Astrocytes: implications for neuroinflammatory pathogenesis of Alzheimer's disease. Curr Alzheimer Res 2011; 8: 67-80.
5. Savchenko VL, McKanna JA, Nikonenko IR and Skibo GG. Microglia and astrocytes in the adult rat brain: comparative immunocytochemical analysis demonstrates the efficacy of lipocortin 1 immunoreactivity. Neuroscience 2000; 96: 195-203.
6. Blasko I, Stampfer-Kountchev M, Robatscher P, Veerhuis R, Eikelenboom P and Grubeck-Loebenstein B. How chronic inflammation can affect the brain and support the development of Alzheimer's disease in old age: the role of microglia and astrocytes. Aging Cell 2004; 3: 169-176.
7. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D and Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 2000; 6: 916-919.
8. Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC and Husemann J. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat Med 2003; 9: 453-457.
9. Gendelman HE. Neural immunity: Friend or foe? J Neurovirol 2002; 8: 474-479.
10. Puffer BA, Sharron M, Coughlan CM, Baribaud F, McManus CM, Lee B, David J, Price K, Horuk R, Tsang M and Doms RW. Expression and coreceptor function of APJ for primate immunodeficiency viruses. Virology 2000; 276: 435-444.
11. Kato S, Gondo T, Hoshii Y, Takahashi M, Yamada M and Ishihara T. Confocal observation of senile plaques in Alzheimer's disease: senile plaque morphology and relationship between senile plaques and astrocytes. Pathol Int 1998; 48: 332-340.
12. Kamphuis W, Middeldorp J, Kooijman L, Sluijs JA, Kooi EJ, Moeton M, Freriks M, Mizee MR and Hol EM. Glial fibrillary acidic protein isoform expression in plaque related astrogliosis in Alzheimer's disease. Neurobiol Aging 2014; 35: 492-510.
13. Blasko I, Veerhuis R, Stampfer-Kountchev M, Saurwein-Teissl M, Eikelenboom P and Grubeck-Loebenstein B. Costimulatory effects of interferon-Γ and interleukin-1β or tumor necrosis factor a on the synthesis of Aβ1-40 and Aβ1-42 by human astrocytes. Neurobiol Dis 2000; 7: 682-689.
14. Wyss-Coray T, Loike JD, Brionne TC, Lu E, Anankov R, Yan F, Silverstein SC and Husemann J. Adult mouse astrocytes degrade amyloid-β in vitro and in situ. Nat Med 2003; 9: 453-457.
15. Pihlaja R, Koistinaho J, Malm T, Sikkilä H, Vainio S and Koistinaho M. Transplanted astrocytes internalize deposited β-amyloid peptides in a transgenic mouse model of Alzheimer's disease. Glia 2008; 56: 154-163.
16. Forloni G, Mangiarotti F, Angeretti N, Lucca E and De Simoni MG. β-amyloid fragment potentiates IL-6 and TNF-α secretion by LPS in astrocytes but not in microglia. Cytokine 1997; 9: 759-762.
17. GE YW and Lahiri D. Regulation of promoter activity of the APP gene by cytokines and growth factors. Ann N Y Acad Sci 2002; 973: 463-467.
18. Kitazawa M, Oddo S, Yamasaki TR, Green KN and LaFerla FM. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci 2005; 25: 8843-8853.
19. Saha RN and Pahan K. Signals for the induction of nitric oxide synthase in astrocytes. Neurochem Int 2006; 49: 154-163.
20. Han X, Chen M, Wang F, Windrem M, Wang S, Shanz S, Xu Q, Oberheim NA, Bekar L, Betstadt S, Silva AJ, Takano T, Goldman SA and Nedergaard M. Forebrain engraftment by human glial progenitor cells enhances synaptic plasticity and learning in adult mice. Cell Stem Cell 2013; 12: 342-353.
21. Horuk R. Chemokine receptors. Cytokine Growth Factor Rev 2001; 12: 313-335.
22. Rossi D and Zlotnik A. The biology of chemokines and their receptors. Ann Rev Immunol 2000; 18: 217-242.
23. Ramesh G, MacLean AG and Philipp MT. Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic pain. Mediators Inflamm 2013; 2013: 20.
24. Hesselgesser J and Horuk R. Chemokine and chemokine receptor expression in the central nervous system. J Neurovirol 1999; 5: 13-26.
25. Dorf ME, Berman MA, Tanabe S, Heesen M and Luo Y. Astrocytes express functional chemokine receptors. J Neuroimmunol 2000; 111: 109-121.
26. Solfrizzi V, D'Introno A, Colacicco AM, Capurso C, Todarello O, Pellicani V, Capurso SA, Pietrarossa G, Santamato V and Capurso A. Circulating biomarkers of cognitive decline and dementia. Clin Chim Acta 2006; 364: 91-112.
27. Tarawneh R and Holtzman DM. Biomarkers in translational research of Alzheimer's disease. Neuropharmacology 2010; 59: 310-322.
28. Westin K, Buchhave P, Nielsen H, Minthon L, Janciauskiene S and Hansson O. CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. PLoS One 2012; 7: e30525.
29. Zhang R, Miller RG, Madison C, Jin X, Honrada R, Harris W, Katz J, Forshew DA and McGrath MS. Systemic immune system alterations in early stages of Alzheimer's disease. J Neuroimmunol 2013; 256: 38-42.
30. Harries LW, Bradley-Smith RM, Llewellyn DJ, Pilling LC, Fellows A, Henley W, Hernandez D, Guralnik JM, Bandinelli S, Singleton A, Ferrucci L and Melzer D. Leukocyte CCR2 expression is associated with mini-mental state examination score in older adults. Rejuvenation Res 2012; 15: 395-404.
31. Alsadany MA, Shehata HH, Mohamad MI and Mahfouz RG. Histone deacetylases enzyme, copper, and IL-8 levels in patients with Alzheimer's disease. Am J Alzheimers Dis Other Demen 2013; 28: 54-61.
32. Kim TS, Lim HK, Lee JY, Kim DJ, Park S, Lee C and Lee CU. Changes in the levels of plasma soluble fractalkine in patients with mild cognitive impairment and Alzheimer's disease. Neurosci Lett 2008; 436: 196-200.
33. Laske C, Stellos K, Stransky E, Seizer P, Akcay O, Eschweiler GW, Leyhe T and Gawaz M. Decreased plasma and cerebrospinal fluid levels of stem cell factor in patients with early Alzheimer's disease. J Alzheimers Dis 2008; 15: 451-460.
34. Kester MI, van der Flier WM, Visser A, Blankenstein MA, Scheltens P and Oudejans CB. Decreased mRNA expression of CCL5 [RANTES] in Alzheimer's disease blood samples. Clin Chem Lab Med 2012; 50: 61-65.
35. Li K, Liu S, Yao S, Wang B, Dai D and Yao L. Interaction between interleukin-8 and methylenetetrahydrofolate reductase genes modulates Alzheimer's disease risk. Dement Geriatr Cogn Disord 2009; 27: 286-291.
36. Venturelli E, Galimberti D, Fenoglio C, Lovati C, Finazzi D, Guidi I, Corra B, Scalabrini D, Clerici F, Mariani C, Forloni G, Bresolin N and Scarpini E. Candidate gene analysis of IP-10 gene in patients with Alzheimer's disease. Neurosci Lett 2006; 404: 217-221.
37. Galimberti D, Venturelli E, Fenoglio C, Lovati C, Guidi I, Scalabrini D, Mariani C, Bresolin N and Scarpini E. IP-10 serum levels are not increased in mild cognitive impairment and Alzheimer's disease. Eur J Neurol 2007; 14: e3-4.
38. Galimberti D, Schoonenboom N, Scheltens P, Fenoglio C, Venturelli E, Pijnenburg YA, Bresolin N and Scarpini E. Intrathecal chemokine levels in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2006; 66: 146-147.
39. Liao Y, Guan ZZ and Ravid R. [Changes of nuclear factor and inflammatory chemotactic factors in brain of patients with Alzheimer's disease]. Zhonghua Bing Li Xue Za Zhi 2011; 40: 585-589.
40. Sokolova A, Hill MD, Rahimi F, Warden LA, Halliday GM and Shepherd CE. Monocyte chemoattractant protein-1 plays a dominant role in the chronic inflammation observed in Alzheimer's disease. Brain Pathol 2009; 19: 392-398.
41. Tripathy D, Thirumangalakudi L and Grammas P. RANTES upregulation in the Alzheimer's disease brain: A possible neuroprotective role. Neurobiol Aging 2010; 31: 8-16.
42. Coughlan CM, McManus CM, Sharron M, Gao Z, Murphy D, Jaffer S, Choe W, Chen W, Hesselgesser J, Gaylord H, Kalyuzhny A, Lee VM, Wolf B, Doms RW and Kolson DL. Expression of multiple functional chemokine receptors and monocyte chemoattractant protein-1 in human neurons. Neuroscience 2000; 97: 591-600.
43. Puma C, Danik M, Quirion R, Ramon F and Williams S. The chemokine interleukin-8 acutely reduces Ca(2+) currents in identified cholinergic septal neurons expressing CXCR1 and CXCR2 receptor mRNAs. J Neurochem 2001; 78: 960-971.
44. Lu W, Maheshwari A, Misiuta I, Fox SE, Chen N, Zigova T, Christensen RD and Calhoun DA. Neutrophil-specific chemokines are produced by astrocytic cells but not by neuronal cells. Brain Res Dev Brain Res 2005; 155: 127-134.
45. Meucci O, Fatatis A, Simen AA, Bushell TJ, Gray PW and Miller RJ. Chemokines regulate hippocampal neuronal signaling and gp120 neurotoxicity. Proc Natl Acad Sci U S A 1998; 95: 14500-14505.
46. Xia M, Qin S, McNamara M, Mackay C and Hyman BT. Interleukin-8 receptor B immunoreactivity in brain and neuritic plaques of Alzheimer's disease. Am J Pathol 1997; 150: 1267-1274.
47. Flynn G, Maru S, Loughlin J, Romero IA and Male D. Regulation of chemokine receptor expression in human microglia and astrocytes. J Neuroimmunol 2003; 136: 84-93.
48. Horuk R, Martin AW, Wang Z, Schweitzer L, Gerassimides A, Guo H, Lu Z, Hesselgesser J, Perez HD, Kim J, Parker J, Hadley TJ and Peiper SC. Expression of chemokine receptors by subsets of neurons in the central nervous system. J Immunol 1997; 158: 2882-2890.
49. Croitoru-Lamoury J, Guillemin GJ, Boussin FD, Mognetti B, Gigout LI, Chéret A, Vaslin B, Le Grand R, Brew BJ and Dormont D. Expression of chemokines and their receptors in human and simian astrocytes: evidence for a central role of TNFα and IFNγ in CXCR4 and CCR5 modulation. Glia 2003; 41: 354-370.
50. Ransohoff R, Hamilton T, Tani M, Stoler M, Shick H, Major J, Estes M, Thomas D and Tuohy V. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. FASEB J 1993; 7: 592-600.
51. Asensio VC, Maier J, Milner R, Boztug K, Kincaid C, Moulard M, Phillipson C, Lindsley K, Krucker T and Fox HS. Interferon-independent, human immunodeficiency virus type 1 gp120-mediated induction of CXCL10/IP-10 gene expression by astrocytes in vivo and in vitro. J Virol 2001; 75: 7067-7077.
52. Biber K, Dijkstra I, Trebst C, De Groot CJ, Ransohoff RM and Boddeke HW. Functional expression of CXCR3 in cultured mouse and human astrocytes and microglia. Neuroscience 2002; 112: 487-497.
53. Bajetto A, Bonavia R, Barbero S, Piccioli P, Costa A, Florio T and Schettini G. Glial and neuronal cells express functional chemokine receptor CXCR4 and its natural ligand stromal cell-derived factor 1. J Neurochem 1999; 73: 2348-2357.
54. Ambrosini E, Remoli ME, Giacomini E, Rosicarelli B, Serafini B, Lande R, Aloisi F and Coccia EM. Astrocytes produce dendritic cell-attracting chemokines in vitro and in multiple sclerosis lesions. J Neuropathol Exp Neurol 2005; 64: 706-715.
55. Deshmane SL, Kremlev S, Amini S and Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009; 29: 313-326.
56. Berger O, Gan X, Gujuluva C, Burns AR, Sulur G, Stins M, Way D, Witte M, Weinand M and Said J. CXC and CC chemokine receptors on coronary and brain endothelia. Mol Med 1999; 5: 795.
57. Albright AV, Shieh JT, Itoh T, Lee B, Pleasure D, O'Connor MJ, Doms RW and González-Scarano F. Microglia express CCR5, CXCR4, and CCR3, but of these, CCR5 is the principal coreceptor for human immunodeficiency virus type 1 dementia isolates. J virol 1999; 73: 205-213.
58. Kim MO, Suh HS, Brosnan CF and Lee SC. Regulation of RANTES/CCL5 expression in human astrocytes by interleukin-1 and interferon-beta. J Neurochem 2004; 90: 297-308.
59. Tanabe S, Heesen M, Berman MA, Fischer MB, Yoshizawa I, Luo Y and Dorf ME. Murine astrocytes express a functional chemokine receptor. J Neurosci 1997; 17: 6522-6528.
60. Gong X, Gong W, Kuhns DB, Ben-Baruch A, Howard OZ and Wang JM. Monocyte chemotactic protein-2 (MCP-2) uses CCR1 and CCR2B as its functional receptors. J Biol Chem 1997; 272: 11682-11685.
61. Andjelkovic AV, Kerkovich D, Shanley J, Pulliam L and Pachter JS. Expression of binding sites for β chemokines on human astrocytes. Glia 1999; 28: 225-235.
62. Renner NA, Ivey NS, Redmann RK, Lackner AA and MacLean AG. MCP-3/CCL7 production by astrocytes: implications for SIV neuroinvasion and AIDS encephalitis. J Neurovirol 2011; 17: 146-152.
63. Serafini B, Columba-Cabezas S, Di Rosa F and Aloisi F. Intracerebral recruitment and maturation of dendritic cells in the onset and progression of experimental autoimmune encephalomyelitis. Am J Pathol 2000; 157: 1991-2002.
64. Ambrosini E, Columba-Cabezas S, Serafini B, Muscella A and Aloisi F. Astrocytes are the major intracerebral source of macrophage inflammatory protein-3a/CCL20 in relapsing experimental autoimmune encephalomyelitis and in vitro. Glia 2003; 41: 290-300.
65. Yoshida H, Imaizumi T, Fujimoto K, Matsuo N, Kimura K, Cui XF, Matsumiya T, Tanji K, Shibata T and Tamo W. Synergistic stimulation, by tumor necrosis factor-a and interferon-?, of fractalkine expression in human astrocytes. Neurosci Lett 2001; 303: 132-136.
66. Meda L, Cassatella MA, Szendrei GI, Otvos L Jr, Baron P, Villalba M, Ferrari D and Rossi F. Activation of microglial cells by beta-amyloid protein and interferon-gamma. Nature 1995; 374: 647-650.
67. Hu J, Akama KT, Krafft GA, Chromy BA and Van Eldik LJ. Amyloid-β peptide activates cultured astrocytes: morphological alterations, cytokine induction and nitric oxide release. Br Res 1998; 785: 195-206.
68. Nakajima K and Kohsaka S. Microglia: activation and their significance in the central nervous system. J Biochem 2001; 130: 169-175.
69. Schubert P and Rudolphi K. Interfering with the pathologic activation of microglial cells and astrocytes in dementia. Alzheimer Dis Assoc Disord 1998; 12 Suppl 2: S21-28.
70. Goldgaber D, Harris HW, Hla T, Maciag T, Donnelly RJ, Jacobsen JS, Vitek MP and Gajdusek DC. Interleukin 1 regulates synthesis of amyloid beta-protein precursor mRNA in human endothelial cells. Proc Natl Acad Sci U S A 1989; 86: 7606-7610.
71. Suo Z, Tan J, Placzek A, Crawford F, Fang C and Mullan M. Alzheimer's β-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40. Br Res 1998; 807: 110-117.
72. Smits HA, Rijsmus A, van Loon JH, Wat JW, Verhoef J, Boven LA and Nottet HS. Amyloid-beta-induced chemokine production in primary human macrophages and astrocytes. J Neuroimmunol 2002; 127: 160-168.
73. Lee YK, Kwak DH, Oh KW, Nam SY, Lee BJ, Yun YW, Kim YB, Han SB and Hong JT. CCR5 deficiency induces astrocyte activation, Abeta deposit and impaired memory function. Neurobiol Learn Mem 2009; 92: 356-363.
74. Ashutosh, Kou W, Cotter R, Borgmann K, Wu L, Persidsky R, Sakhuja N and Ghorpade A. CXCL8 protects human neurons from amyloid-beta-induced neurotoxicity: relevance to Alzheimer's disease. Biochem Biophys Res Commun 2011; 412: 565-571.
75. Lai W, Wu J, Zou X, Xie J, Zhang L, Zhao X, Zhao M, Wang Q and Ji J. Secretome analyses of Abeta (1-42) stimulated hippocampal astrocytes reveal that CXCL10 is involved in astrocyte migration. J Proteome Res 2013; 12: 832-843.
76. Sheng J, Zhu S, Jones R, Griffin W and Mrak R. Interleukin-1 promotes expression and phosphorylation of neurofilament and tau proteins in vivo. Exp Neurol 2000; 163: 388-391.
77. Oh JW, Drabik K, Kutsch O, Choi C, Tousson A and Benveniste EN. CXC chemokine receptor 4 expression and function in human astroglioma cells. J Immunol 2001; 166: 2695-2704.
78. Allan Butterfield D, Griffin S, Munch G and Pasinetti GM. Amyloid β-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists. J Alzheimers Dis 2002; 4: 193-201.
79. Bolin LM, Murray R, Lukacs NW, Strieter RM, Kunkel SL, Schall TJ and Bacon KB. Primary sensory neurons migrate in response to the chemokine RANTES. J Neuroimmunol 1998; 81: 49-57.
80. Xia MQ and Hyman BT. Chemokines/chemokine receptors in the central nervous system and Alzheimer's disease. J Neurovirol 1999; 5: 32-41.
81. Bagri A, Gurney T, He X, Zou YR, Littman DR, Tessier-Lavigne M and Pleasure SJ. The chemokine SDF1 regulates migration of dentate granule cells. Development 2002; 129: 4249-4260.
82. Noda M and Suzumura A. Sweepers in the CNS: microglial migration and phagocytosis in the alzheimer disease pathogenesis. Int J Alzheimers Dis 2012; 2012: 891087.
83. Fiala M, Zhang L, Gan X, Sherry B, Taub D, Graves MC, Hama S, Way D, Weinand M and Witte M. Amyloid-beta induces chemokine secretion and monocyte migration across a human blood--brain barrier model. Mol Med 1998; 4: 480.
84. Man SM, Ma YR, Shang DS, Zhao WD, Li B, Guo DW, Fang WG, Zhu L and Chen YH. Peripheral T cells overexpress MIP-1a to enhance its transendothelial migration in Alzheimer's disease. Neurobiol Aging 2007; 28: 485-496.
85. Liu YJ, Guo DW, Tian L, Shang DS, Zhao WD, Li B, Fang WG, Zhu L and Chen YH. Peripheral T cells derived from Alzheimer's disease patients overexpress CXCR2 contributing to its transendothelial migration, which is microglial TNF-α-dependent. Neurobiol Aging 2010; 31: 175-188.
86. Zhou Y, Sonobe Y, Akahori T, Jin S, Kawanokuchi J, Noda M, Iwakura Y, Mizuno T and Suzumura A. IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes. J Immunol 2011; 186: 4415-4421.
87. Peterson PK, Hu S, Salak-Johnson J, Molitor TW and Chao CC. Differential production of and migratory response to β chemokines by human microglia and astrocytes. J Infect Dis 1997; 175: 478-481.
88. Wu J, Bie B, Yang H, Xu JJ, Brown DL and Naguib M. Suppression of central chemokine fractalkine receptor signaling alleviates amyloid-induced memory deficiency. Neurobiol Aging 2013; 34: 2843-2852.
89. Meda L, Bonaiuto C, Szendrei GI, Ceska M, Rossi F and Cassatella MA. beta-Amyloid(25-35) induces the production of interleukin-8 from human monocytes. J Neuroimmunol 1995; 59: 29-33.
90. Wang Q, Xu Y, Chen JC, Qin YY, Liu M, Liu Y, Xie MJ, Yu ZY, Zhu Z and Wang W. Stromal cell-derived factor 1alpha decreases beta-amyloid deposition in Alzheimer's disease mouse model. Brain Res 2012; 1459: 15-26.
91. Dash PK and Moore AN. Enhanced processing of APP induced by IL-1 beta can be reduced by indomethacin and nordihydroguaiaretic acid. Biochem Biophys Res Commun 1995; 208: 542-548.
92. Fagarasan MO and Aisen PS. IL-1 and anti-inflammatory drugs modulate A beta cytotoxicity in PC12 cells. Brain Res 1996; 723: 231-234.
93. Qiu Z, Parsons KL and Gruol DL. Interleukin-6 selectively enhances the intracellular calcium response to NMDA in developing CNS neurons. J Neurosci 1995; 15: 6688-6699.
94. Gilliland CT, Salanga CL, Kawamura T, Trejo J and Handel TM. The chemokine receptor CCR1 is constitutively active, which leads to G protein-independent, beta-arrestin-mediated internalization. J Biol Chem 2013; 288: 32194-32210.
95. Vukic V, Callaghan D, Walker D, Lue LF, Liu QY, Couraud PO, Romero IA, Weksler B, Stanimirovic DB and Zhang W. Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis 2009; 34: 95-106.
96. Xia M and Hyman BT. GROa/KC, a chemokine receptor CXCR2 ligand, can be a potent trigger for neuronal ERK1/2 and PI-3 kinase pathways and for tau hyperphosphorylation-a role in Alzheimer's disease? J Neuroimmunol 2002; 122: 55-64.
97. Kiyota T, Yamamoto M, Xiong H, Lambert MP, Klein WL, Gendelman HE, Ransohoff RM and Ikezu T. CCL2 accelerates microglia-mediated Abeta oligomer formation and progression of neurocognitive dysfunction. PLoS One 2009; 4: e6197.
98. Kiyota T, Gendelman HE, Weir RA, Higgins EE, Zhang G and Jain M. CCL2 affects beta-amyloidosis and progressive neurocognitive dysfunction in a mouse model of Alzheimer's disease. Neurobiol Aging 2013; 34: 1060-1068.
99. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C and Luster AD. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 2007; 13: 432-438.
100. Naert G and Rivest S. CC chemokine receptor 2 deficiency aggravates cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. J Neurosci 2011; 31: 6208-6220.
101. Madrigal JL, Leza JC, Polak P, Kalinin S and Feinstein DL. Astrocyte-derived MCP-1 mediates neuroprotective effects of noradrenaline. J Neurosci 2009; 29: 263-267.
102. Fuhrmann M, Bittner T, Jung CK, Burgold S, Page RM, Mitteregger G, Haass C, LaFerla FM, Kretzschmar H and Herms J. Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci 2010; 13: 411-413.
103. Lee S, Varvel NH, Konerth ME, Xu G, Cardona AE, Ransohoff RM and Lamb BT. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am J Pathol 2010; 177: 2549-2562.
104. Hanzel CE, Pichet-Binette A, Pimentel LSB, Iulita MF, Allard S, Ducatenzeiler A, Do Carmo S and Cuello AC. Neuronal driven pre-plaque inflammation in a transgenic rat model of Alzheimer's disease. Neurobiol Aging 2014; 35: 2249-62.
105. Nash KR, Lee DC, Hunt JB Jr, Morganti JM, Selenica ML, Moran P, Reid P, Brownlow M, Guang-Yu Yang C, Savalia M, Gemma C, Bickford PC, Gordon MN and Morgan D. Fractalkine overexpression suppresses tau pathology in a mouse model of tauopathy. Neurobiol Aging 2013; 34: 1540-1548.
106. Cho SH, Sun B, Zhou Y, Kauppinen TM, Halabisky B, Wes P, Ransohoff RM and Gan L. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J Biol Chem 2011; 286: 32713-32722.
107. Laske C, Stellos K, Eschweiler GW, Leyhe T and Gawaz M. Decreased CXCL12 (SDF-1) plasma levels in early Alzheimer's disease: a contribution to a deficient hematopoietic brain support? J Alzheimers Dis 2008; 15: 83-95.
108. Parachikova A, Nichol KE and Cotman CW. Short-term exercise in aged Tg2576 mice alters neuroinflammation and improves cognition. Neurobiol Dis 2008; 30: 121-129.
109. Nichol KE, Poon WW, Parachikova AI, Cribbs DH, Glabe CG and Cotman CW. Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J Neuroinflammation 2008; 5: 13.
110. Parachikova A and Cotman CW. Reduced CXCL12/CXCR4 results in impaired learning and is downregulated in a mouse model of Alzheimer disease. Neurobiol Dis 2007; 28: 143-153.
111. Kang J, Jiang L, Goldman SA and Nedergaard M. Astrocyte-mediated potentiation of inhibitory synaptic transmission. Nat Neurosci 1998; 1: 683-692.
112. Innocenti B, Parpura V and Haydon PG. Imaging extracellular waves of glutamate during calcium signaling in cultured astrocytes. J Neurosci 2000; 20: 1800-1808.
113. Bezzi P, Domercq M, Brambilla L, Galli R, Schols D, De Clercq E, Vescovi A, Bagetta G, Kollias G, Meldolesi J and Volterra A. CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 2001; 4: 702-710.
114. Combarros O, Infante J, Llorca J, Pena N, Fernandez-Viadero C and Berciano J. The chemokine receptor CCR5-Delta32 gene mutation is not protective against Alzheimer's disease. Neurosci Lett 2004; 366: 312-314.
115. Avdoshina V, Biggio F, Palchik G, Campbell LA and Mocchetti I. Morphine induces the release of CCL5 from astrocytes: potential neuroprotective mechanism against the HIV protein gp120. Glia 2010; 58: 1630-1639.
116. Xia MQ, Bacskai BJ, Knowles RB, Qin SX and Hyman BT. Expression of the chemokine receptor CXCR3 on neurons and the elevated expression of its ligand IP-10 in reactive astrocytes: in vitro ERK1/2 activation and role in Alzheimer's disease. J Neuroimmunol 2000; 108: 227-235.
117. Franciosi S, Ryu JK, Choi HB, Radov L, Kim SU and McLarnon JG. Broad-spectrum effects of 4-aminopyridine to modulate amyloid β1-42-induced cell signaling and functional responses in human microglia. J Neurosci 2006; 26: 11652-11664.
118. Mukherjee P and Pasinetti GM. The role of complement anaphylatoxin C5a in neurodegeneration: implications in Alzheimer's disease. J neuroimmunol 2000; 105: 124-130.
119. Jauneau AC, Ischenko A, Chan P and Fontaine M. Complement component anaphylatoxins upregulate chemokine expression by human astrocytes. FEBS Lett 2003; 537: 17-22.
120. Appay V and Rowland-Jones SL. RANTES: a versatile and controversial chemokine. Trends Immunol 2001; 22: 83-87.
121. Lin MS, Hung KS, Chiu WT, Sun YY, Tsai SH, Lin JW and Lee YH. Curcumin enhances neuronal survival in N-methyl-d-aspartic acid toxicity by inducing RANTES expression in astrocytes via PI-3K and MAPK signaling pathways. Prog NeuroPsychopharmacol Biol Psychiatry 2011; 35: 931-938.
122. Kalliomäki J, Jonzon B, Huizar K, O'Malley M, Andersson A and Simpson DM. Evaluation of a novel chemokine receptor 2 (CCR2)-antagonist in painful diabetic polyneuropathy. Scandinavian J Pain 2013; 4: 77-83.
123. Murata M, Furusyo N and Hayashi J. P273 Beneficial effect of C-C chemokine receptor type 5 antagonist, as an add-on treatment for HIV-1 patients with virological response but no immunological response. Intl J Antimicrobial Agents 2013; 42 Suppl 2: S128.